E 20 More Psychedelic Stocks

On average the above 10 stocks went UP 25.6% last week.

Segment Two

Six other psychedelic stocks trade exclusively on the Canadian Securities Exchange (CSE) and in Canadian dollars (go here to convert into USD) and are worth keeping an eye on going forward, namely:

  1. PharmaTher Inc. (PHRM) +92.9% to $0.27
    • PharmaTher, a wholly-owned subsidiary of Newscope Capital Corporation, is focused on the research and development of psychedelic pharmaceuticals, such as ketamine and psilocybin, to treat disorders such as Parkinson’s disease, depression, traumatic brain injury, and stroke, using panaceAI, its drug repurposing artificial intelligence platform.
      • PanaceAI leverages machine learning to curate and rank the most relevant drug interactions, binding affinities, drug-disease similarities, and structural comparison tools to make data-driven drug predictions and will serve as the Company’s product pipeline engine.
      • Upon further validation, panaceAI will be commercialized to acquire partnership opportunities with biotechnology and pharmaceutical companies globally.
      • For more information on the company visit its website here.
  2. Psyched Wellness Ltd. (PSYC) +52.9% to $0.26
    • Psyched Wellness is dedicated to the production and distribution of psychedelic mushrooms and associated consumer packaged goods led by its flagship mushroom extract product, Amanita Muscaria infused tinctures which, when micro-dosed, has anecdotally been shown to soothe the body, ease physical distress and help with sleeping.
    • For more information on the company visit its website here.
  3. Entheon Biomedical Corp. (ENTBF) +42.0% to $0.71
    • Entheon is focused on developing and commercializing a portfolio of safe and effective Dimethyltryptamine-based (DMT) psychedelic therapeutic products for the purposes of treating addiction and substance use disorders and to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
    • For more information on the company visit its website here.
  4. Aion Therapeutic Inc. (AION) +/-0%
    • Its mission is to create an array of novel patent-protected therapeutic formulations using unique combinations of medical cannabis (THC & CBD) with psychedelic mushrooms (psilocybin), fungi (edible mushrooms), and other psychedelic and natural therapies to benefit patients with illnesses such as cancer, psychiatric disorders, addiction (opioid and alcohol), viral infections, obesity, chronic inflammation, and other such medical issues.
    • Acquired PCAI Pharma and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited, a private corporation incorporated and operating under the laws of Jamaica, which provides Aion with:
      • a unique opportunity in that it is one of the very few countries in the world where mushrooms (both edible and psychedelic) have never been made illegal.
      • a major research and development opportunity through its partnership with Apollon Formularies Jamaica, Ltd. which allows Aion to focus on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals in a legal environment for this type of discovery.
    • The company believes it is in the unique position of being able to build a large portfolio of blocking patents while most of the rest of the world faces legal hurdles that limit efforts in this type of research and discovery and to that end has
      • Filed five patent applications with the United States Patent and Trademark Office pertaining to new treatments combining healing compounds in medical cannabis with healing compounds from mushrooms.
    • For more information on the company visit its website here.
  5. Core One Labs Inc. (COOL) +/-0%
    • Sold its non-core assets in mid-October to allow it to focus on developing its thin strip technologies for use with psilocybin, as well as expanding the newly acquired psychedelic assets.
    • Has entered into a Letter of Intent to acquire all of the outstanding share capital of Vocan Biotechnologies Inc.
      • Vocan is a genetic engineering and biosynthesis research firm developing a proprietary fermentation system for the production of psilocybin API for the treatment of mental health illnesses, including addictions.
    • For more information on the company visit its website here.
  6. Pure Extracts Technology Corp. (PULL) +3.3% to $0.63
    • The Company is currently focused on the cannabis and hemp sectors and is presently expanding its business to include functional (non-psychedelic) mushrooms extraction processes compatible with its existing infrastructure by the end of 2020.
      • To that end, the company has received a Dealers License from Health Canada which will enable them to buy, sell, test, and produce psychedelics in an EU GMP environment.
      • For more information on the company visit its website here.
View single page >> |

Disclosure:This article discusses one or more penny stocks and/or microcaps. Such stocks are easily manipulated; do your own careful due diligence.

Visit   more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.